Turkish experience for the effects of raloxifene hydrochloride on endometrium and mammographic breast density in postmenopausal women with low bone mineral density
Background: To assess the changes in the endometrial tissue and breast density in postmenopausal osteopenic and osteoporotic women after usage of raloxifene for 18 months. Material/Method: We studied the changes in parameters like endometrial thickness and mammographic breast density due to raloxifene in 354 postmenopausal patents with low bone mineral density applied to our hospital's menopause polyclinic. 234 subjects were assigned to the raloxifene group, 120 to the control group. 22 (9.4%) of 234 subjects in the raloxifene group and 15 (12.5%) of 120 subjects in control group left the study during the 18-month treatment period. Results: Although the baseline endometrial thickness values were similar in both groups, there was a small reduction in the thickness in the raloxifene group at the 18th month. There was no change in breast density in the raloxifene group, whereas in the control group breast density increased in many subjects. Although hot flashes were seen frequently more in the raloxifene group, all other adverse events were similar in both groups. Conclusion: Daily therapy with 60mg raloxifene does not stimulate the endometrium and does not influence breast density.